The wealth of human tumor genomic data and mechanistic understanding of drivers of disease progression has allowed for a more refined stratification of tumor subtypes and disease states enabling an opportunity to select a particular targeted therapy for a patient’s cancer. Precision medicine is used for treating cancer patients with individualized, targeted therapies based on the specific molecular profile of their tumors, with the aim of providing more effective care and improved clinical responses.
IDEAYA, with its capabilities and approach to precision medicine, strives to be a leader in this “Golden Age” of oncology drug discovery and development with a diversified approach for developing therapies based on direct targeting of oncogenic pathways, synthetic lethality and biomarker-enabled immuno-oncology.
Our organization was founded with the vision of establishing the leading precision medicine company with capabilities that enable an integrated approach for biomarker and small molecule drug discovery and development to broadly address unmet needs in cancer. Our capabilities include target and biomarker discovery integrated with small molecule therapeutics, from early discovery through clinical development.
”The emergence of highly efficient genome editing tools allows us to leverage decades of genetic interaction data from model organisms, such as yeast, to identify synthetic lethal combinations in human cancer cells. Mining those data is now highly feasible, and the potential for drug discovery and development is unprecedented. IDEAYA has assembled a team of scientific advisors and scientists with expertise ranging from basic enzymology to quantitative systems biology to yeast and mammalian genetics to clinical research. As such, we are ideally situated to realize this potential.John Petrini, Ph.D.Memorial Sloan Kettering Cancer Center, IDEAYA SAB Member